{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:35:39Z","timestamp":1778780139411,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T00:00:00Z","timestamp":1229990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2009,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The current study was a phase 2 open\u2013label study to evaluate the efficacy and tolerability of single\u2010agent sorafenib in the treatment of advanced HCC patients in a hepatitis B\u2013endemic Asian population.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Patients with advanced hepatocellular carcinoma (HCC) received sorafenib at a dose of 400 mg twice daily in 4\u2010week cycles. Tumor response was assessed every 3 cycles using Response Evaluation Criteria in Solid Tumors criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Fifty\u2010one patients were enrolled in the study and were treated with sorafenib for at least 12 weeks. The median age was 56 years (range, 28\u201079 years). Approximately 90% had hepatitis B virus\u2013related HCC. Thirty\u2010six (71%) patients had underlying Child\u2010Pugh A cirrhosis, 13 (26%) Child\u2010Pugh B, and 2 (3%) Child\u2010Pugh C. Four (8%) patients achieved partial responses, and 9 (18%) patients had stable disease for at least 12 weeks. The median overall survival was 5 months (range, 4\u201017 months). Patients without extrahepatic spread, particularly without lung metastasis (<jats:italic>P<\/jats:italic>&lt;.01), are more likely to benefit from sorafenib treatment. The most common toxicities were diarrhea (67%), malaise (55%), and hand\u2010foot\u2010skin reaction (54%). The majority of patients had transient liver function derangement. Patients with and without underlying portal vein thrombosis had similar therapeutic benefits and likewise shared a similar treatment\u2010related toxicity profile with sorafenib treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Single\u2010agent sorafenib demonstrates good efficacy and acceptable tolerability in treating an advanced HCC patient population in a hepatitis B\u2013endemic area. The presence of lung metastasis predicts poor response to sorafenib in advanced HCC patients. Cancer 2009. \u00a9 2009 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24029","type":"journal-article","created":{"date-parts":[[2008,12,23]],"date-time":"2008-12-23T10:48:40Z","timestamp":1230029320000},"page":"428-436","source":"Crossref","is-referenced-by-count":118,"title":["Phase 2 open\u2010label study of single\u2010agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B\u2013endemic Asian population"],"prefix":"10.1002","volume":"115","author":[{"given":"Thomas","family":"Yau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelvin K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sin Ho","family":"Chok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tan To","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheung Tat","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronnie T.","family":"Poon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,7]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1440"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.13.12.1555"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880801)62:3<479::AID-CNCR2820620306>3.0.CO;2-L"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81683-9"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_7_8_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4509","volume-title":"Randomized Phase III Trial of Sorafenib Versus Placebo in Asian Patients With advanced Hepatocellular Carcinoma","author":"Cheng A\u2010L","year":"2008"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00130-1"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.0201"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23878"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8099"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23684"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23878"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji315"},{"key":"e_1_2_7_17_2","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.4509","volume-title":"Randomized Phase III trial of Sorafenib Versus Placebo in Asian Patients With Advanced Hepatocellular Carcinoma","author":"Cheng YK","year":"2008"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.3441"},{"key":"e_1_2_7_19_2","first-page":"20","article-title":"Is sorafenib (S) safe and effective in patients (pts) with hepatocellular carcinoma (HCC) and Child\u2010Pugh B (CPB) cirrhosis?","volume":"26","author":"Abou\u2010Alfa DA","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.45.1590"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/14639230500236818"},{"key":"e_1_2_7_22_2","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Hepatobiliary Cancers. V.2.2008. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/hepatobiliary.pdf"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24029","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:41:14Z","timestamp":1760265674000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24029"}},"subtitle":["Presence of lung metastasis predicts poor response"],"short-title":[],"issued":{"date-parts":[[2009,1,7]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,1,15]]}},"alternative-id":["10.1002\/cncr.24029"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24029","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,7]]}}}